[1] Advani A. Positioning time in range in diabetes management[J].Diabetologia, 2020, 63(2):242-252.
[2] Heinemann L, Freckmann G, Müller-Wieland D, et al. Critical reappraisal of the time-in-range: alternative or useful addition to glycated hemoglobin?[J].J Diabetes Sci Technol,2020,14(5):922-927.
[3] Lin R, Brown F, James S, et al. Continuous glucose monitoring: a review of the evidence in type 1 and 2 diabetes mellitus[J]. Diabet Med, 2021,38(5): e14528.
[4] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020 年版)[J].中华糖尿病杂志,2021,13(4):315-409.
[5] Battelino T, Danne T, Bergenstal R M,et al.Targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range[J].Diabetes Care,2019,42(8):1593-1603.
[6] Vigersky R A,McMahon C.The relationship of hemoglobin a1c to time-in-range in patients with diabetes[J]. Diabetes Technol Ther, 2019, 21(2):81-85.
[7] Bellido V,Pinés-Corrales P J,Villar-Taibo R, et al. Time-in-range for monitoring glucose control: is it time for a change?[J]. Diabetes Res Clin Pract,2021, 177:108917.
[8] Battelino T,Alexander C M,Amiel S A, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement[J]. Lancet Diabetes Endocrinol,2023,11(1):42-57.
[9] Rodbard D.Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes[J]. Diabetes Technol Ther, 2017,19(S3): S25-S37.
[10] Beck R W,Bergenstal R M,Cheng P,et al. The relationships between time in range, hyperglycemia metrics, and HbA1c[J]. J Diabetes Sci Technol, 2019, 13(4):614-626.
[11] Mo Y, Ma X, Lu J,et al.Defining the target value of the coefficient of variation by continuous glucose monitoring in Chinese people with diabetes[J]. J Diabetes Investig, 2021,12(6):10251034.
[12] Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes[J].Diabetes Care, 2018, 41(11):2370-2376.
[13] Sheng X, Xiong G H, Yu P F, et al. The correlation between time in range and diabetic microvascular complications utilizing information management platform[J]. Int J Endocrinol, 2020,15:8879085.
[14] Beck R W,Bergenstal R M,Riddlesworth T D,et al.Validation of time in range as an outcome measure for diabetes clinical trials[J]. Diabetes Care, 2019, 42(3):400-405.
[15] 中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南(2021年版)[J].中华糖尿病杂志,2021,13(8):762-784.
[16] Lu J, Ma X, Shen Y, et al. Time in range is associated with carotid intima-media thickness in type 2 diabetes[J]. Diabetes Technol Ther,2020,22(2):72-78.
[17] Lu J Y, Wang C F, Shen Y, et al. Time in range in relation to all cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study[J]. Diabetes Care, 2021, 44(2): 549-555.
[18] Bergenstal R,Kvist K,Hachmann N E,et al. Derived time-in-range is associated with mace in type 2 diabetes:data from the devote trial[J]. Diabetes,2020,25(6):69.
[19] Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease[J]. BMJ Open Diabetes Res Care, 2020, 8(1): e000991.
[20] Yang J, Yang X, Zhao D, et al. Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy[J]. J Diabetes Investig, 2021, 12(5):828-836.
[21] Li M, Wu K, Chang J, et al.A retrospective study on the time in range of blood glucose and type 2 diabetic peripheral neuropathy[J]. Biomed Res Int, 2022, 28:274.
[22] 中华医学会糖尿病学分会.中国血糖监测临床应用指南(2021年版) [J].中华糖尿病杂志, 2021,13 (10):936-947.
[23] Johnson M L,Martens T W,Criego A B, et al. Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice[J].Diabetes Technol Ther, 2019, 21(S2): S217S225.
[24] 戴冬君,陆静毅,张 磊,等.应用葡萄糖在目标范围内时间评价2型糖尿病血糖控制情况的适宜切点分析[J].中华医学杂志, 2020,100(38):2990-2996.
[25] Gao F, Ma X, Peng J, et al. The effect of acarbose on glycemic variability in patients with type 2 diabetes mellitus using premixed insulin compared to metformin (aim): an open-label randomized trial[J]. Diabetes Technol Ther, 2020, 22(4):256-264.
[26] Luo M, Kong X, Wang H, et al.Effect of dapagliflozin on glycemic variability in patients with type 2 diabetes under insulin glargine combined with other oral hypoglycemic drugs[J].J Diabetes Res,2020,24: 666.
[27] Heise T,Kaplan K,Haahr H L.Day-to-day and within-day variability in glucose-lowering effect between insulin degludec and insulin glargine (100 U/ml and 300 U/ml): a comparison across studies[J].J Diabetes Sci Technol, 2018, 12(2):356-363.
[28] Battelino T,Danne T,Edelman S V,et al. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: the head-to-head randomized controlled InRange trial[J]. Diabetes Obes Metab, 2023, 25(2):545-555.
[29] Philis T A,Aroda V R,De Block C,et al. Higher derived time in range with ideglira versus insulin glargine u100 in people with type 2 diabetes[J]. J Diabetes Sci Technol, 2023, 29:193.